InnoTherapy vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how InnoTherapy (246960) and Abbott Laboratories (ABT) compare, as of Aug 21, 2026.
As of Aug 21, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: InnoTherapy trades at KRW 1,994 versus a fair value of KRW 482 (-76%), while Abbott Laboratories trades at $114 versus $74.79 (-34%).
InnoTherapy
246960.KQ · KRW · Health Care
-76%
upside to fair value
overvalued
PriceKRW 1,994
Fair ValueKRW 482
Quality24/100
Abbott Laboratories
ABT · USD · Health Care
-34%
upside to fair value
overvalued
Price$114
Fair Value$74.79
Quality67/100
Get comparisons like this free by email every month: the most undervalued quality stocks.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
InnoTherapyAbbott Laboratories
Valuation
—P/E (TTM)27.7×
—P/S (TTM)3.89×
—P/B3.36×
7.8×EV/EBITDA15.1×
—PEG1.47×
—Dividend yield2.1%
—Dividend per share$2.44
Profitability
-12%Net margin14%
-8%Operating margin13%
-13%Return on equity12%
-3%Return on assets6%
Growth
238%Revenue growth (YoY)8%
290.4%Avg. growth/yr (3Y)0.5%
105.8%Avg. growth/yr (5Y)5.1%
Balance & size
0.50×Debt / equity0.19×
$38MMarket cap$175B
expensiveGrowth qualityhealthy
Abbott Laboratories leads: 4 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
InnoTherapyof which business quality 24 · market factors 35Abbott Laboratoriesof which business quality 66 · market factors 55
ProfitabilityMargins and returns on capital today
4
50
Quality GrowthAre margins and returns improving?
72
47
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
7
65
Low VolatilityCalm price path (market factor)
62
83
MomentumPrice trend over the last 3–12 months (market factor)
28
45
52W MomentumDistance to the 52-week high (market factor)
16
42
Net IssuanceBuybacks instead of dilution
50
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
InnoTherapy
Asset-BasedKRW 482
1 of 1 models see the stock below the current price.
Abbott Laboratories
DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
InnoTherapy
Bear KRW 359Fair Value KRW 482Bull KRW 719
KRW 1,994 = current price (white tick)
Abbott Laboratories
Bear $51.13Fair Value $74.79Bull $94.43
$114 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
InnoTherapy · Health Care
Quality score24 · bottom 25%
Fair value upside-76% · bottom 25%
Abbott Laboratories · Health Care
Quality score67 · Top 25%
Fair value upside-34% · below median
Bottom line
As of Aug 21, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: InnoTherapy trades at KRW 1,994 versus a fair value of KRW 482 (-76%), while Abbott Laboratories trades at $114 versus $74.79 (-34%).
Abbott Laboratories has the higher quality score (67/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
